



## Specifications

<b>Quantity</b>	5E6 Cells per vial, 1 mL
<b>Product Format</b>	1 vial of frozen cells
<b>Shipping</b>	Shipped on dry ice
<b>Storage Conditions</b>	Liquid nitrogen immediately upon receipt
<b>Recovery Medium</b>	MEM+15% FBS+1% P.S+1% NEAA+0.11 mg/mL Sodium Pyruvate
<b>Growth medium</b>	MEM+15% FBS+1% P.S+1% NEAA+0.11 mg/mL Sodium Pyruvate+1 µg/mL Blasticidin+0.5 µg/mL Puromycin
<b>Note</b>	None
<b>Freezing Medium</b>	90% FBS+10% DMSO
<b>Growth properties</b>	Adherent
<b>Growth Conditions</b>	37°C, 5% CO <sub>2</sub>
<b>Mycoplasma Testing</b>	The cell line has been screened to confirm the absence of Mycoplasma species.
<b>Safety considerations</b>	Biosafety Level 2
<b>Note</b>	It is recommended to expand the cell culture and store a minimum of 10 vials at an early passage for potential future use.

## Materials

Reagent	Manufacturer/Catalogue No.
MEM	gibco/11095-080
Fetal Bovine Serum	Cegrogen biotech/A0500-3010
NEAA	Pricella/PB180424
Pen/Strep	Thermo/15140-122
Sodium Pyruvate Solution	Viva Cell/C3546-0100
Blasticidin	Genomeditech/GM-040404
Puromycin	Genomeditech/GM-040401
Biotinylated Human IgE Isotype Control; His-Avi Tag (Anti-RSV)	Genomeditech/GM-88131AB
Streptavidin	Yeasen/35101ES03
Anti-IGHE hIgG1 Reference Antibody(Omalbio)	Genomeditech/GM-87960MAB
Anti-FcεRI hIgG1 Antibody (1E7)	Genomeditech/GM-88159AB
GMOne-Step 2.0 Luciferase Reporter Gene Assay Kit	Genomeditech/GM-040513

## Figures




Figure 1 | Response to Biotinylated Human IgE Isotype. On day one, FcεRIα Reporter RBL-2H3 Cell Line (Cat. GM-C40137) were seeded in a 96-well plate at 1E4 cells/well and incubated for at least 4 hours before removing the supernatant. Simultaneously, serial dilutions of human IgE (Cat. GM-88131AB) were prepared and added to FcεRIα Reporter RBL-2H3 Cell Line for overnight incubation. The next day, after supernatant removal, streptavidin (2 μg/well) was added and incubated for 3 hours. The firefly luciferase activity was measured using the Luciferase Reporter Assay Kit (Genomeditech). The maximum induction fold reached approximately [49.8]. Data are shown as drug mass concentration.




Figure 2 | Response to Omalizumab. On day one, FcεRIα Reporter RBL-2H3 cells (Cat. GM-C40137) were seeded in a 96-well plate at 1E4 cells/well and incubated for at least 4 hours before removing the supernatant. Simultaneously, serially diluted omalizumab and 20 ng/well Human IgE (Cat. GM-88131AB) were co-incubated in assay buffer for 1 hour, then added to the FcεRIα Reporter RBL-2H3 cells for overnight incubation. The next day, after supernatant removal, streptavidin (2 μg/well) was added and incubated for 3 hours. The firefly luciferase activity was measured

using the Luciferase Reporter Assay Kit (Genomeditech). The maximum induction fold reached approximately [10.6]. Data are shown as drug mass concentration.




Figure 3 | Response to Omalizumab. On day one, FcεRIα Reporter RBL-2H3 cells (Cat. GM-C40137) were seeded in a 96-well plate at 1E4 cells/well and incubated for at least 4 hours before removing the supernatant. Simultaneously, serially diluted omalizumab and 20 ng/well Human IgE (Cat. GM-88131AB) were co-incubated in assay buffer for 1 hour, then added to the FcεRIα Reporter RBL-2H3 cells for overnight incubation. The next day, after supernatant removal, streptavidin (2 µg/well) was added and incubated for 3 hours. The firefly luciferase activity was measured using the Luciferase Reporter Assay Kit (Genomeditech). The maximum induction fold reached approximately [10.6]. Data are shown as drug molar concentration.




Figure 4 | FcεRIα Reporter RBL-2H3 Cell Line (Cat. GM-C40137) was determined by flow cytometry using Anti-FcεRI hIgG1 Antibody (1E7) (Cat. GM-88159AB).

## Cell Recovery

Recovery Medium: MEM+15% FBS+1% P.S+1% NEAA+0.11 mg/mL Sodium Pyruvate

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at  $-70^{\circ}\text{C}$ . Storage at  $-70^{\circ}\text{C}$  will result in loss of viability.

- a) Thaw the vial by gentle agitation in a  $37^{\circ}\text{C}$  water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 - 3 minutes).
- b) Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.
- c) Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium and spin at approximately  $176 \times g$  for 5 minutes. Discard supernatant.
- d) Resuspend cell pellet with the recommended recovery medium. And dispense into appropriate culture dishes.
- e) Incubate the culture at  $37^{\circ}\text{C}$  in a suitable incubator. A 5%  $\text{CO}_2$  in air atmosphere is recommended if using the medium described on this product sheet.

## Cell Freezing

Freezing Medium: 90% FBS+10% DMSO

- a) Centrifuge at  $176 \times g$  for 3 minutes to collect cells.
- b) Resuspend the cells in pre-cooled freezing medium and adjust the cell density to  $5 \times 10^6$  cells/mL.
- c) Aliquot 1 mL into each vial.
- d) Place the vial in a controlled-rate freezing container and store at  $-80^{\circ}\text{C}$  for at least 1 day, then transfer to liquid nitrogen as soon as possible.

## Cell passage

Growth medium: MEM+15% FBS+1% P.S+1% NEAA+0.11 mg/mL Sodium Pyruvate+1  $\mu\text{g}/\text{mL}$  Blasticidin+0.5  $\mu\text{g}/\text{mL}$  Puromycin

For the first 1 to 2 passages post-resuscitation, use the recovery medium. Once the cells have stabilized, switch to a growth medium.

- a) Remove and discard culture medium.
- b) Briefly rinse the cell layer with PBS to remove all traces of serum that contains trypsin inhibitor.
- c) Add 1.0 mL of 0.25% (w/v) Trypsin-EDTA solution to dish and observe cells under an inverted microscope until cell layer is dispersed (usually within 2 to 3 minutes at  $37^{\circ}\text{C}$ ).
- d) Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at  $37^{\circ}\text{C}$  to facilitate dispersal.
- e) Add 2.0 mL of growth medium to mix well and aspirate cells by gently pipetting.
- f) After centrifugation, resuspend the pellet and add appropriate aliquots of the cell suspension to new culture vessels.
- g) Incubate cultures at  $37^{\circ}\text{C}$ .

**Subcultivation Ratio: A subcultivation ratio of 1:3 - 1:4 is recommended**

**Medium Renewal: Every 2 to 3 days**

## Notes

- a) RBL-2H3 cells exhibit a polygonal adherent morphology when cultured at low density. As the cell density increases, rounded cells begin to appear. The cell density should not exceed 80%, as over-confluence can lead to rounding of the cells and significant detachment.

## Related Products

c-Kit:SCF	
<a href="#">H_c-Kit(CD117) GNNK(-) 293 Blockade Reporter Cell Line</a>	<a href="#">Cynomolgus_c-Kit(CD117) GNNK(-) CHO-K1 Cell Line</a>
<a href="#">H_c-Kit(CD117) GNNK(-) CHO-K1 Cell Line</a>	<a href="#">H_c-Kit(CD117) GNNK(-) HEK-293 Cell Line</a>
<a href="#">H_c-Kit(CD117) GNNK(+) CHO-K1 Cell Line</a>	
<a href="#">Anti-c-Kit(CD117) hIgG1 Antibody(barzolvolimab)</a>	<a href="#">Anti-c-Kit(CD117) hIgG1 Antibody(briquilimab)</a>
<a href="#">Anti-c-Kit(CD117) hIgG1 Reference Antibody(barbio)</a>	
<a href="#">Biotinylated Human c-Kit(CD117) Protein; His-Avi Tag</a>	<a href="#">Biotinylated Human SCF Protein; His-Avi Tag</a>
<a href="#">Cynomolgus c-Kit(CD117) Protein; His Tag</a>	<a href="#">Human c-Kit(CD117) D4-D5 Protein; His Tag</a>
<a href="#">Human c-Kit(CD117) Protein; hFc Tag</a>	<a href="#">Human c-Kit(CD117) Protein; His Tag</a>
<a href="#">Human SCF Protein; His Tag</a>	<a href="#">Human SCF Protein; mFc Tag</a>
MRGPRX2	
<a href="#">H_MRGPRX2 Gqi5 Reporter CHO-K1 Cell Line</a>	<a href="#">Tango-H_MRGPRX2 CHO-K1 Cell Line</a>
<a href="#">Cynomolgus_MRGPRX2 CHO-K1 Cell Line</a>	<a href="#">Cynomolgus_MRGPRX2 HEK-293 Cell Line</a>
<a href="#">Flag-Mouse_Mrgprb2 CHO-K1 Cell Line</a>	<a href="#">Flag-Rat_Mrgprb3 HEK-293 Cell Line</a>
<a href="#">H_MRGPRX2 CHO-K1 Cell Line</a>	<a href="#">H_MRGPRX2 HEK-293 Cell Line</a>
<a href="#">H_MRGPRX2 HMC-1 Cell Line</a>	<a href="#">H_MRGPRX2 RBL-2H3 Cell Line</a>
IGHE(FcεRIα)	
<a href="#">Membrane IgE(mIgE) HEK-293 Cell Line</a>	
<a href="#">Anti-FcεRI hIgG1 Antibody (1E7)</a>	<a href="#">Anti-IGHE hIgG1 Reference Antibody(Omalbio)</a>
<a href="#">Biotinylated Human IgE D2-D4 Protein; His-Avi Tag</a>	<a href="#">Cynomolgus IgE D2-D4 Protein; His Tag</a>
<a href="#">Human FCER1A Protein; His Tag</a>	<a href="#">Human FCER2(CD23) Protein; His Tag</a>
<a href="#">Human IgE D2-D4 Protein; His Tag</a>	

## License Agreement:

**By purchasing and using this cell line product, the user voluntarily agrees to accept and abide by the following policies:**

- This cell line product is restricted to research use only and shall not be used for any commercial purposes.

- This product is strictly prohibited from being used in the diagnosis or treatment of human or animal diseases, and shall not be directly used in experiments involving humans.
- Users and their contractors engaged for their benefit may use this material and its derivatives only within the agreed research scope; modification of the material is not permitted, nor may it be distributed, sold, transferred, or otherwise provided to any other entity (including affiliates).
- If use beyond the above scope is required, prior written permission from Genomeditech (Shanghai) Co.,Ltd. must be obtained. For details, please contact Genomeditech (Shanghai) Co.,Ltd.

Genomeditech